• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Ifosfamide plasma clearance in relation to polymorphic debrisoquine oxidation.

作者信息

Philip P A, Lewis L D, James C A, Rogers H J

机构信息

Department of Clinical Pharmacology, United Medical School, Guy's Hospital, London Bridge, U.K.

出版信息

Cancer Chemother Pharmacol. 1988;22(4):321-4. doi: 10.1007/BF00254239.

DOI:10.1007/BF00254239
PMID:3168145
Abstract

Ifosfamide (IF) pharmacokinetics and the plasma (NBP)-alkylating activity were determined in 33 patients with different tumours after the administration of IF as single-agent chemotherapy. All subjects had been phenotyped for debrisoquine oxidation. There is a lack of correlation between the debrisoquine metabolic ratio (DMR) and either the total plasma clearance of IF (CLIF) or the AUC of the plasma NBP-alkylating activity.

摘要

相似文献

1
Ifosfamide plasma clearance in relation to polymorphic debrisoquine oxidation.
Cancer Chemother Pharmacol. 1988;22(4):321-4. doi: 10.1007/BF00254239.
2
Evidence for the polymorphic oxidation of debrisoquine in the Thai population.泰国人群中异喹胍多态性氧化的证据。
Br J Clin Pharmacol. 1990 Feb;29(2):244-7. doi: 10.1111/j.1365-2125.1990.tb03627.x.
3
Polymorphic oxidation of debrisoquine in bladder cancer.膀胱癌中异喹胍的多态性氧化
Ann Med. 1990 Jun;22(3):157-60. doi: 10.3109/07853899009147261.
4
Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.鹰爪豆碱和异喹胍的多态性氧化：相关药物遗传学实体。
Clin Pharmacol Ther. 1982 Feb;31(2):184-6. doi: 10.1038/clpt.1982.29.
5
Lack of relationship between tolbutamide metabolism and debrisoquine oxidation phenotype.甲苯磺丁脲代谢与异喹胍氧化表型之间缺乏相关性。
Eur J Clin Pharmacol. 1987;33(4):397-402. doi: 10.1007/BF00637637.
6
Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies.美托洛尔代谢与异喹胍氧化多态性——群体与家系研究
Br J Clin Pharmacol. 1985 Dec;20(6):555-66. doi: 10.1111/j.1365-2125.1985.tb05112.x.
7
The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol.异喹胍氧化表型与普萘洛尔的药代动力学和药效学之间的关系。
Br J Clin Pharmacol. 1984 Jun;17(6):679-85. doi: 10.1111/j.1365-2125.1984.tb02403.x.
8
Genetically determined oxidation capacity and the disposition of debrisoquine.遗传决定的氧化能力与异喹胍的代谢
Br J Clin Pharmacol. 1983 Apr;15(4):443-50. doi: 10.1111/j.1365-2125.1983.tb01528.x.
9
Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine.司巴丁N-氧化缺陷与异喹胍4-羟化的药物遗传学共变。
Eur J Clin Pharmacol. 1980 Feb;17(2):153-5. doi: 10.1007/BF00562624.
10
Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population.日本人群中三种测试探针（美托洛尔、异喹胍和司巴丁）代谢率之间与遗传决定的氧化多态性的相关性。
Br J Clin Pharmacol. 1990 Jan;29(1):111-5. doi: 10.1111/j.1365-2125.1990.tb03609.x.

引用本文的文献

1
3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio.3,4-脱氢去甲丙咪嗪，一种由4-羟基去甲丙咪嗪形成的新型去甲丙咪嗪代谢物，它会影响CYP2D6代谢率。
Drug Metab Dispos. 2006 Sep;34(9):1563-74. doi: 10.1124/dmd.105.008920. Epub 2006 Jun 16.
2
Ifosfamide clinical pharmacokinetics.异环磷酰胺的临床药代动力学。
Clin Pharmacokinet. 1994 Jun;26(6):439-56. doi: 10.2165/00003088-199426060-00003.
3
Ifosfamide pharmacokinetics.

本文引用的文献

1
A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.对英国白人人群中异喹胍氧化遗传多态性的家系及群体研究。
J Med Genet. 1980 Apr;17(2):102-5. doi: 10.1136/jmg.17.2.102.
2
Defective oxidation of drugs: pharmacokinetic and therapeutic implications.药物氧化缺陷：药代动力学及治疗学意义
Clin Pharmacokinet. 1982 Jan-Feb;7(1):1-22. doi: 10.2165/00003088-198207010-00001.
3
Genetically determined oxidation capacity and the disposition of debrisoquine.遗传决定的氧化能力与异喹胍的代谢
Invest New Drugs. 1991 Nov;9(4):305-11. doi: 10.1007/BF00183570.
Br J Clin Pharmacol. 1983 Apr;15(4):443-50. doi: 10.1111/j.1365-2125.1983.tb01528.x.
4
The comparative pharmacology of cyclophosphamide and ifosfamide.环磷酰胺与异环磷酰胺的比较药理学
Semin Oncol. 1982 Dec;9(4 Suppl 1):2-7.
5
Interindividual variations in drug disposition. Clinical implications and methods of investigation.药物处置的个体间差异。临床意义及研究方法。
Clin Pharmacokinet. 1983 Sep-Oct;8(5):371-7. doi: 10.2165/00003088-198308050-00001.
6
Rapid gas chromatographic determination of ifosfamide in biological fluids.生物流体中异环磷酰胺的快速气相色谱测定法。
J Chromatogr. 1984 Nov 9;311(1):194-8. doi: 10.1016/s0378-4347(00)84709-x.
7
Assessment of the drug metabolism capacity of the liver.肝脏药物代谢能力的评估。
Br J Clin Pharmacol. 1982 Nov;14(5):631-51. doi: 10.1111/j.1365-2125.1982.tb04950.x.
8
Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide.一些关于环磷酰胺和异环磷酰胺微粒体代谢过程中形成的活性中间体的研究。
Biochem Pharmacol. 1974 Jan 1;23(1):115-29. doi: 10.1016/0006-2952(74)90318-9.
9
Metabolism of iphosphamide (2-(2-chloroethylamino)-3-(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide) and production of a toxic iphosphamide metabolite.
Cancer Res. 1973 May;33(5):1016-22.
10
Unexpected toxicity in patients treated with iphosphamide.接受异环磷酰胺治疗的患者出现意外毒性。
Cancer Res. 1972 May;32(5):921-4.